Skip to main content
. 2024 May 30;134(14):e176230. doi: 10.1172/JCI176230

Figure 6. TME and immunotherapy-associated predictive biomarkers by site of metastases.

Figure 6

(A) Heatmap of median cell abundance and gene expression by biopsy site. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 when compared with kidney. Frequency of biomarker-positive samples for (B) PDL1 IHC (SP142 antibody), (C) TMB-High (≥ 10 mut/Mb), and (D) dMMR/MSI-High. NK, natural killer; CTLA4, The cytotoxic T-lymphocyte-associated antigen-4; TIM3, T cell immunoglobulin domain and mucin domain3; LAG3, Lymphocyte-Activation Gene3; PD-1, programmed death-1; PDL1, programmed death ligand-1; PDL2, programmed death ligand-2; GI, gastrointestinal.